Operation 'p53 Hunt' to combat cancer: Theaflavins in action

Frontiers in Bioscience - Scholar

Volumn 4 S, Issue 1, 2012, Pages 300-320

  Mohanty, Suchismita ^a   Adhikary, Arghya ^a   Chakrabarty, Samik ^a   Sa, Gaurisankar ^a   Das, Tanya ^a  

^a BOSE INSTITUTE   (India)

Author keywords

Angiogenesis; Apoptosis; CSC; Drug Resistance; Metastasis; P53; Review; Theaflavins

Indexed keywords

CATHEPSIN D; ENDOSTATIN; EPHRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; GLUCOSE TRANSPORTER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 8; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MUTANT PROTEIN; PLANT MEDICINAL PRODUCT; PROTEIN P53; RESTIN; THEAFLAVIN; THROMBOSPONDIN; THROMBOSPONDIN 1; UVOMORULIN; VASCULOTROPIN; ANTIOXIDANT; BIFLAVONOID; CATECHIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER PREVENTION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG RESISTANCE; DRUG TARGETING; GENE INACTIVATION; GLYCOLYSIS; HUMAN; METASTASIS; MOLECULAR INTERACTION; NONHUMAN; OVARY CANCER; OXIDATIVE PHOSPHORYLATION; PROSTATE CARCINOMA; PROTEIN FUNCTION; PROTEIN TARGETING; TEA; TREATMENT FAILURE; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; WILD TYPE; ANIMAL; METABOLISM; NEOPLASM; PATHOLOGY; REVIEW;

CAMELLIA SINENSIS;

ANIMALS; ANTIOXIDANTS; BIFLAVONOIDS; CATECHIN; HUMANS; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865693231     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/270     Document Type: Article

References (164)

1. Miller R, H. L McLeod: Pharmacogenomics of cancer chemotherapy-induced toxicity. J Support Oncol 5, 9-14 (2007)
2. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3, 768-780 (2003)
3. Surh YJ: Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat Res 428, 305-27 (1999)
4. Das T, G Sa, E Paszkiewicz-Kozik, C Hilston, L Molto, P Rayman, D Kudo, K Biswas, RM Bukowski, JH Finke, CS Tannenbaum: GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells. Cancer Res 69, 3095-3104 (2009)
5. Das T, G Sa, E Paszkiewicz-Kozik, C Hilston, L Molto, P Rayman, D Kudo, K Biswas, RM Bukowski, JH Finke, CS Tannenbaum: Renal cell carcinoma tumors induce T cell apoptosis through receptor-dependent and receptorindependent pathways. J Immunol 180, 4687-4696 (2008)
6. Das T, G Sa, C Hilston, D Kudo, P Rayman, K Biswas, L Molto, R Bukowski, B Rini, JH Finke, CS Tannenbaum: GM1 and tumor necrosis factor-alpha, overexpressed in renal cell carcinoma, synergize to induce T-cell apoptosis. Cancer Res 68, 2014-2023 (2008)
7. Sa G, T Das, C Moon, CM Hilston, PA Rayman, BI Rini, CS Tannenbaum, JH Finke: Renal cell carcinoma tumors induce T cell apoptosis through receptor-dependent and receptor-independent pathways. J Immunol 180, 4687- 4696, (2008)
8. Bhattacharyya S, DMS Hossain, S Mohanty, GS Sen, S Chattopadhyay, S Banerjee, J Chakraborty, K Das, D Sarkar, T Das, G Sa: Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts. Cell Mol Immunol 7, 306-315 (2010)
9. Bhattacharyya S, D Mandal, GS Sen, S Pal, S Banerjee, L Lahiry, JH Finke, CS Tannenbaum, T Das, G Sa: Tumorinduced oxidative stress perturbs nuclear factor-kappaB activity-augmenting tumor necrosis factor-alpha-mediated T-cell death: protection by curcumin. Cancer Res 67, 362- 370 (2007)
10. Bhattacharyya S, D Mandal, B Saha, GS Sen T Das, G Sa: Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction. J Biol Chem 282, 15954-15964 (2007)
11. Pal S, S Bhattacharya, T Choudhuri, GK Datta, T Das, G Sa: Amelioration of immune cell number depletion and potentiation of depressed detoxification system of tumorbearing mice by curcumin. Cancer Detection Prevention 29, 470-478 (2005)
12. Gopalakrishnan A, AN Kong: Anticarcinogenesis by dietary phytochemicals: cytoprotection by Nrf2 in normal cells and cytotoxicity by modulation of transcription factors NF-kappa B and AP-1 in abnormal cancer cells. Food Chem Toxicol 46, 1257-1270 (2008)
13. Manson MM: Cancer prevention-the potential for diet to modulate molecular signalling. Trends Mol Med 9, 11-18 (2003)
14. Sa G, T Das: Anti cancer effects of curcumin: cycle of life and death. Cell Div 3, 14 (2008)
15. Chattopadhyay S, S Bhattacharyya, B Saha, J Chakraborty, S Mohanty, DMS Hossain, S Banerjee, K Das, G Sa, T Das: Tumor-shed PGE(2) impairs IL2Rgammac-signaling to inhibit CD4 T cell survival: regulation by theaflavins. PLoS One 4, e7382. (2009)
16. Bhattacharyya A, D Mandal, L Lahiry, S Bhattacharyya, S Chattopadhyay, UK Ghosh, G Sa, T Das: Black Tea-Induced Amelioration of Hepatic Oxidative Stress through Antioxidative Activity in EAC-Bearing Mice. J Environ Pathol Toxicol Oncol 26, 245-254 (2007)
17. Mandal D, S Bhattacharyya, L Lahiry, S Chattopadhyay, G Sa, T Das: Black tea-induced decrease in IL-10 and TGF-beta of tumor cells promotes Th1/Tc1 response in tumor-bearer. Nutrition Cancer 58, 213-221 (2007)
18. Mandal D, A Bhattacharyya, L Lahiry, S Bhattacharyya, G Sa, T Das. Tumor-induced thymic involution via Inhibition of IL-7Ralpha and its JAK-STAT signaling pathway: Protection by Black Tea. Int Immunopharmacol 6, 433-44 (2006)
19. Mandal D, L Lahiry, A Bhattacharyya, S Chattopadhyay, M Siddiqi, G Sa, Das T: Black tea protects thymocytes in tumor-bearers by differential regulation of intracellular ROS in tumor cells and thymocytes. J Environ Toxicol Pathol Oncol 24, 91-104 (2005)
20. Bhattacharyya A, D Mandal, L Lahiry, G Sa, T. Das: Black tea protects immunocytes from tumor-induced apoptosis by changing Bcl-2/Bax ratio. Cancer Lett 209, 147-154 (2004)
21. Bhattacharyya A, G Sa, T Das, M Siddiqi. Black teainduced cellular survival: Evidence for reduced toxicity and enhanced immunity in mice under stress. Int J Tea Sci 2, 34-39 (2003)
22. Yang CS, P Maliakal, X Meng: Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 42, 25- 54 (2002)
23. Wang ZY, MT Huang, YR Lou, JG Xie, KR Reuhl, HL Newmark, CT Ho, CS Yang, AH Conney: Inhibitory effects of black tea, green tea, decaffeinated black tea, and decaffeinated green tea on ultraviolet B light-induced skin carcinogenesis in 7, 12-dimethylbenz[a]anthracene-initiated SKH-1 mice. Cancer Res 54, 3428-3435 (1994)
24. Sun X, H Shimizu, K Yamamoto: Identification of a novel p53 promoter element involved in genotoxic stressinducible p53 gene expression. Mol cell biol 15, 4489-4496 (1995)
25. Wang S, WS El-Deiry: p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. Cancer Res 66, 6982-6989 (2006)
26. Bode AM, Z Dong: Post-translational modification of p53 in tumorigenesis. Nature Rev Cancer. 4, 793-805 (2004)
27. Helton ES, X Chen: p53 modulation of the DNA damage response. J Cell Biochem 100, 883-896 (2007)
28. Riley T, E Sontag, P Chen, A Levine: Transcriptional control of human p53-regulated genes. Nature Rev Mol Cell Biol 9, 402-412 (2008)
29. Kan CE, JT Patton, GR Stark, MW Jackson: p53- mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21. Cancer Res 67, 9862-9868 (2007)
30. Menendez D, A Inga, MA Resnick: The expanding universe of p53 targets. Nat Rev Cancer 9, 724-737 (2009)
31. Opitz OG, Y Suliman, WC Hahn, H Harada, HE Blum, AK Rustgi: Cyclin D1 overexpression and p53 inactivation immortalize primary oral keratinocytes by a telomeraseindependent mechanism. J Clin Invest 108, 725-732 (2001)
32. Agarwal ML, WR Taylor, MV Chernov, OB Chernova, GR Stark: The p53 network. J Biol Chem 273, 1-4 (1998)
33. Brown CJ, S Lain, CS Verma, AR Fersht, DP Lane: Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9, 862-873 (2009)
34. Hainaut P, M Hollstein: p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77, 81-137 (2000)
35. Warburg O: On the origin of cancer cells. Science 123, 309-314 (1956)
36. Yoseph F, M Armoni, E Karnieli: The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 64, 2627-2633 (2004)
37. Kondoh H, ME Lleonart, J Gil, J Wang, P Degan, G Peters, D Martinez, A Carnero, D Beach. Glycolytic enzymes can modulate cellular lifespan. Cancer Res 65, 177-185 (2005)
38. Bensaad K, A Tsuruta, MA Selak, M Vidal, K Nakano, R Bartrons, E Gotleib, KH Vousden: TIGAR, a p53- inducible regulator of glycolysis and apoptosis. Cell 126, 107-120 (2006)
39. Kawauchi K, K Araki, K Tobiume, N Tanaka: p53 regulates glucose metabolism though an IKK-NF-kappaB pathway and inhibits cell transformation. Nature Cell Biol 10, 611-618 (2008)
40. Burns DM, JD Richter: CPEB regulation of human cellular senescence, energy metabolism, and p53 mRNA translation. Genes Dev. 22, 3449-3460 (2008)
41. Bergers G, LE Benjamin: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 3, 401-410 (2003)
42. Yu EY, E Yu, GE Meyer, MK Brawer: The relation of p53 protein nuclear accumulation and angiogenesis in human prostatic carcinoma. Prostate Cancer Prostatic Dis 1, 39-44 (1997)
43. Takahashi Y, CD Bucana, KR Cleary, LM Ellis: p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer 79, 34-38 (1998)
44. Gasparini G, N Weidner, S Maluta, F Pozza, P Boracchi, M Mezzetti, A Testolin, P Bevilacqua: Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int J Cancer 55, 739-744 (1993)
45. Gasparini G, N Weidner, P Bevilacqua, S Maluta, P Palma Dalla, O Caffo, M Barbareschi, P Boracchi, E Marubini, F Pozza: Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12, 454-466 (1994)
46. Forsythe JA, BH Jiang, NV Iyer, F Agani, SW Leung, RD. Koos, GL Semenza: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor1. Mol Cell Biol 16, 4604-4613 (1996)
47. Ravi R, B Mookerjee, ZM Bhujwalla, CH Sutter, D Artemov, Q Zeng, LE Dillehay, A Madan, GL Semenza, A Bedi: Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14, 34-44 (2000)
48. Pal S, K Datta, D Mukhopadhyay: Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 61, 6952-6957 (2001)
49. Ueba T, T Nosaka, JA Takahashi, F Shibata, RZ Florkiewicz, B Vogelstein, Y Oda, H Kikuchi, M Hatanaka: Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Proc Natl Acad Sci USA 91, 9009-9013 (1994)
50. Sherif ZA, S Nakai, KF Pirollo, A Rait, EH Chang: Downmodulation of bFGF-binding protein expression following restoration of p53 function. Cancer Gene Ther 8, 771-782 (2001)
51. Subbaramaiah K, N Altorki, WJ Chung, JR Mestre, A Sampat, AJ Dannenberg: Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 274, 10911-10915 (1999)
52. Dameron KM, OV Volpert, MA Tainsky, N Bouck: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265, 1582-1584 (1994)
53. Nishimori H, T Shiratsuchi, T Urano, Y Kimura, K Kiyono, K Tatsumi, S Yoshida, M Ono, M Kuwano, Y Nakamura, T Tokino: A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 15, 2145- 2150 (1997)
54. Dohn M, J Jiang, X. Chen: Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene 20, 6503-6515 (2001)
55. Dodelet VC, EB Pasquale: Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 19, 5614- 5619 (2000)
56. O'Reilly MS, T Boehm, Y Shing, N Fukai, G Vasios, WS Lane, E Flynn, JR Birkhead, BR Olsen, J Folkman: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285 (1997)
57. Ramchandran R, M Dhanabal, R Volk, MJ Waterman, M Segal, H Lu, B Knebelmann, VP Sukhatme: Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun 255, 735-739 (1999)
58. Xu R, ZY Yao, L Xin, Q Zhang, TP Li, RB Gan: NC1 domain of human type VIII collagen (alpha 1) inhibits bovine aortic endothelial cell proliferation and causes cell apoptosis. Biochem Biophys Res Commun 289, 264-268(2001)
59. Sun Y, M Wicha, WR Leopold: Regulation of metastasisrelated gene expression by p53: a potential clinical implication. Mol Carcinog 24, 25-28 (1999)
60. Sun Y, L Wenger, JL Rutter, CE Brinckerhoff, HS Cheung: p53 down-regulates human matrix metalloproteinase- 1 (collagenase-1) gene expression. J Biol Chem 274, 11535- 11540 (1999)
61. Toschi E, R Rota, A Antonini, G Melillo, MC Capogrossi: Wild-type p53 gene transfer inhibits invasion and reduces matrix metalloproteinase-2 levels in p53-mutated human melanoma cells. J Invest Dermatol 114,1188-1194 (2000)
62. Bheda A, KE Creek, L Pirisi: Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes. Oncogene 27, 4315-43223 (2008)
63. Ueba T, T Nosaka, JA Takahashi, F Shibata, RZ Florkiewica, B Vogelstein, Y Oda, H Kikuchi, M Hatanaka: Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Proc Natl Acad Sci USA 91, 9009-9013 (1994)
64. Chin KV, K Ueda, I Pastan, MM Gottesman: Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255, 459-462 (1992)
65. Mashimo T, M Watabe, S Hirota: The expression of the KAI1 gene, tumor metastasis suppressor, is directly activated by p53. Proc Natl Acad Sci USA 95, 1130-1131 (1998)
66. Liu J, M Zhan, JA Hannay, P Das, SV Bolshakov, D Kotilingam, D Yu, AF Lazar, RE Pollock, D Lev: Wildtype p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis.Mol Cancer Res 4, 803-810 (2006)
67. Parra M, M Jardí, M Koziczak, Y Nagamine, P Cánoves: p53 Phosphorylation at serine 15 is required for transcriptional induction of the plasminogen activator inhibitor-1 (PAI-1) gene by the alkylating agent N-methyl-N'-nitro-Nnitrosoguanidine. J Biol Chem 276, 36303-36310 (2001)
68. Eitel JA, K Vishehsaraei, MR Saadatzadeh, JR Bhavsar, MP Murphy, KE Pollok, LD Mar Mayo: PTEN and p53 are required for hypoxia induced expression of maspin in glioblastoma cells. Cell Cycle 8, 896-901 (2009)
69. Adhikary A, S Mohanty, L Lahiry, DMS Hossain, S Chakraborty, T Das: Theaflavins retard human breast cancer cell migration by inhibiting NF-kappaB via p53-ROS crosstalk. FEBS Lett 584, 7-14 (2010)
70. Lowe SW, HE Ruley: Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis.Genes Dev 7(4), 535-45 (1993)
71. Haupt S, M Berger, Z Goldberg, Y Haupt: Apoptosis- the p53 network. J Cell Sci 116, 4077-85 (2003)
72. Chipuk JE, DR Green: Dissecting p53-dependent apoptosis. Cell Death Differ 13, 994-1002 (2006)
73. Meulmeester E, AG Jochemsen: p53: a guide to apoptosis. Curr Cancer Drug Targets 8, 87-97(2008)
74. Oda E, R Ohki, H. Murasawa: Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288, 1053-8 (2000)
75. Nakano K, KH Vousden: PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7, 683-94 (2001)
76. Robles AI, NA Bemmels, AB Foraker, CC Harris: APAF-1 is a transcriptional target of p53 in DNA damageinduced apoptosis. Cancer Res. 61, 6660-4 (2001)
77. Li YZ, DY Lu, WQ Tan, JX Wang, PF Li: p53 initiates apoptosis by transcriptionally targeting the antiapoptotic protein ARC. Mol Cell Biol 28, 564-574 (2008)
78. Yao H, P Li, BJ Venters: Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis. J Biol Chem. 283, 20060-20068 (2008)
79. Kuribayashi K, G Krigsfeld, W Wang: TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther 7, 2034-2038 (2008)
80. Maecker HL, C Koumenis, AJ Giaccia: p53 promotes selection for Fas mediated apoptotic resistance. Cancer Res 60, 4638-4644 (2000)
81. Wolff S, S Erster, G Palacios, UM Moll: p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity. Cell Res 18, 733-744 (2008)
82. Ravi R, B Mookerjee, Y Hensbergen, GC Bedi, A Giordano, WS El-Deiry, EJ Fuchs, A Bedi: p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300.Cancer Res 58, 4531-4536 (1998)
83. Wu RC, M Blumenthal, X Li, AH Schönthal: Loss of cellular adhesion to matrix induces p53-independent expression of PTEN tumor suppressor. BMC Mol Biol 3,11 (2002)
84. Hermeking H: p53 enters the microRNA world. Cancer Cell 12, 414-8 (2007)
85. Salas NR, J Palacios, G Moreno, J de Castro, M González- Barón, C Gamallo: Correlation of p53 oncoprotein expression with chemotherapy response in small cell lung carcinomas. Lung Cancer 34, 67-74 (2001)
86. El-Deiry WS: The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22, 7486-7495 (2003)
87. O'Connor PM, J Jackman, I Bae, TG Myers, SJ Fan, M Mutoh, DA Scudiero, A Monks, EA Sausville, JN Weinstein, S Friend, AJ Fornace, KW Kohn: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57, 4285-4300 (1997)
88. Weinstein JN, TG Myers, PM O'Connor, SH Friend, AJ Fornace, KW Kohn, T Fojo, SE Bates, LV Rubinstein, NL Anderson, JK Buolamwini, WW vanOsdol, AP Monks, DA Scudiero, EA Sausville, DW Zaharevitz, B Bunow, VN Viswanadhan, GS Johnson, RE Wittes, KD Paull: An information intensive approach to the molecular pharmacology of cancer. Science 275, 343-349 (1997)
89. Lowe SW, S Bodis, A McClatchey, L Remington, HE Ruley, DE Fisher, DE Housman, T Jacks: p53 status and the efficacy of cancer therapy in vivo. Science 266, 807- 810 (1994)
90. Schmitt CA, SW Lowe: Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo. Blood Cells Mol. Dis 27, 206-216 (2001)
91. Lowe SW, HE Ruley, T Jacks, DE Housman: p53- dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967 (1993)
92. Schmitt CA, JS Fridman, M Yang, S Lee, E Baranov, RM Hoffman, SW Lowe: A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109, 335-346 (2002)
93. Bosari S, G Viale, U Radaeli, P Bossi, E Bonoldi, G Coggi: p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 24, 1175-1179 (1993)
94. Rusch V, D Klimstra, E Venkatraman, J Oliver, N Martini, R Gralla, M Kris, E Dmitrovsky: Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advancednon-small cell lung cancer. Cancer Res 55, 5038-5042 (1995)
95. Weller M: Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 292, 435-445 (1998)
96. Bähr O, W Wick, MJ Weller: Modulation of MDR/MRP by wild-type and mutant p53. Clin Invest 107, 643-646 (2001)
97. Wang Q, WT Beck: Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res 58, 5762-5769 (1998)
98. Bean LN, GR Stark: Regulation of the accumulation and function of p53 by phosphorylation of two residues within the domain that binds to Mdm2. J Biol Chem 277, 1864-71 (2002)
99. Shangary S, S Wang: Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 14, 5318- 5324 (2008)
100. Kawaguchi K, Y Oda, A Sakamoto, T Saito, S Tamiya, Y Iwamoto, M Tsuneyoshi: Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years. Mod Pathol 15, 878-888 (2002)
101. Eischen CM, JD Weber, MF Roussel, CJ Sherr, JL Cleveland: Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13, 2658-2669 (1999)
102. Leng RP, Y Lin, W Ma, H Wu, B Lemmers, S Chung, JM Parant, G Lozano, R Hakem, S Benchimol: Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112, 779-791 (2003)
103. Katayama H, K Sasai, H Kawai, ZM Yuan, J Bondaruk, F Suzuki, S Fujii, RB Arlinghaus, BA Czerniak, S Sen: Phosphorylation by aurora kinase A induces Mdm2- mediated destabilization and inhibition of p53. Nature Genet 36, 55-62 (2004)
104. Pohler E, AL Craig, J Cotton, L Lawrie, JF Dillon, P Ross, N Kernohan, TR Hupp: The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol. Cell Proteomics 3, 534-547 (2004)
105. Hastak K, RK Paul, MK Agarwal, VS Thakur, AR. Amin, S Agrawal, RM Sramkoski, JW Jacobberger, MW Jackson, GR Stark, ML Agarwal: DNA synthesis from unbalanced nucleotide pools causes limited DNA damage that triggers ATR-CHK1-dependent p53 activation. Proc Natl Acad Sci U S A 105, 6314-6319 (2008)
106. Stiewe T, CC Theseling, BM Pützer: Transactivationdeficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem 277, 14177-85 (2002)
107. Stiewe T, CC Theseling, BM Pützer, JT Marques, D Rebouillat, CV Ramana, J Murakami, JE Hill, A Gudkov, RH Silverman, G R Stark, BR Williams: Down-regulation of p53 by double-stranded RNA modulates the antiviral response. J Virol 79, 11105-11114 (2005)
108. Mathupala SP, C Heese, PL Pedersen: Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem 272, 22776-22780 (1997)
109. Ma W, HJ Sung, JY Park, S Matoba, PM Hwang: A pivotal role for p53: balancing aerobic respiration and glycolysis. J Bioenerg Biomembr 39, 243-6 (2007)
110. Giuriato S, S Ryeom, AC Fan, P Bachireddy, RC Lynch, MJ Rioth, JV Riggelen, AM Kopelman, E Passegue, F Tang, J Folkman, DW Felsher: Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci USA 103, 16266-16271 (2006)
111. Holmgren L, G Jackson, J Arbiser: p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma. Oncogene 17, 819-824 (1998)
112. Fontemaggi G, S Dell'Orso, D Trisciuoglio, T Shay, E Melucci, F Fazi, I Terrenato, M Mottolese, P Muti, E Domany, DD Bufalo, S Strano, G Blandino: The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol 16, 1086-1093 (2009)
113. Khromova NV, PB Kopnin, EV Stepanova, LS Agapova, BP Kopnin: p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway. Cancer Lett 276, 143-151 (2009)
114. Adorno M, M Cordenonsi, M Montagner, S Dupont, C Wong, B Hann, A Solari, S Bobisse, MB Rondina, V Guzzardo, AR Parenti, A Rosato, S Bicciato, A Balmain, S Piccolo: A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137, 87-98 (2009)
115. Bukholm IK, JM Nesland, R Karesen, U Jacobsen, AL Borresen-Dale: Expression of E-cadherin and its relation to the p53 protein status in human breast carcinomas. Virchows Arch 431, 317-321(1997)
116. Brosh R, V Rotter: When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9, 701- 713 (2009)
117. Tsang W, FYF Ho, K Fung, S Kong, T Kwok: P53- R175H mutant gains new function in regulation of doxorubicin-induced apoptosis, Int. J. Cancer 114, 331-336 (2005)
118. Lim LY, N Vidnovic, LW Ellisen, CO Leong: Mutant p53 mediates survival of breast cancer cells. Br J Cancer 101, 1606-12 (2009)
119. Kim TH, SY Lee, JH Rho, NY Jeong, YH Soung, WS Jo, DY Kang, SH Kim, YH Yoo: Mutant p53 (G199V) gains antiapoptotic function through signal transducer and activator of transcription 3 in anaplastic thyroid cancer cells. Mol Cancer Res 7, 1645-1654 (2009)
120. Lowe SW, HE Ruley, T Jacks, DE Housman: p53- dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967 (1993)
121. Chin KV, K Ueda, I Pastan, MM Gottesman: Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255, 459-462 (1992)
122. Zhang Z, X Deng, X Ren, B Zhang, X Chen, J Yang, H Ding, J Sui, X Song: Expression of mutant p53 and of the multidrug resistant proteins P-glycoprotein and glutathione Stransferase- pi correlated in colorectal adenocarcinoma. Scand J Gastroenterol 45, 925-934 (2010) [Epub ahead of print].
123. Lahiry L, B Saha, J Chakraborty, A Adhikary, S Mohanty, DM Hossain, S Banerjee, K Das, G Sa, T Das. Theaflavins target Fas/caspase-8 and Akt/pBad pathways to induce apoptosis in p53-mutated human breast cancer cells. Carcinogenesis 31, 259-68 (2010)
124. Nomura M, T Takahashi, N Nagata, K Tsutsumi, S Kobayashi, T Akiba, K Yokogawa, S Moritani, K Miyamoto: Inhibitory mechanisms of flavonoids on insulinstimulated glucose uptake in MC3T3-G2/PA6 adipose cells. Biol Pharm Bull 31, 1403-9 (2008)
125. Lahiry L, B Saha, J Chakraborty, S Bhattacharyya, S Chattopadhyay, S Banerjee, T Choudhuri, D Mandal, A Bhattacharyya, G Sa, T Das: Contribution of p53-mediated Bax transactivation in theaflavin-induced mammary epithelial carcinoma cell apoptosis. Apoptosis 13, 771-781 (2008)
126. Bertram B, H Bartsch: Cancer prevention with green tea: reality and wishful thinking. Wien Med Wochenschr 152, 153-158 (2002)
127. Beltz LA, DK Bayer, AL Moss, IM Simet: Mechanisms of cancer prevention by green and black tea polyphenols. Anticancer Agents Med Chem 6, 389-406 (2006)
128. Shankar S, S Ganapathy, SR Hingorani, RK Srivastava: EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci 13, 440- 452 (2008)
129. Siddiqui IA, N Zaman, MH Aziz, SR Reagan-Shaw, S Sarfaraz, VM Adhami, N Ahmad, S Raisuddin, H Mukhtar: Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas. Carcinogenesis 27, 833-839 (2006)
130. Bhattacharyya A, L Lahiry, D Mandal, G Sa, T Das: Black Tea Induces Tumor Cell Apoptosis by Bax Translocation, Loss in Mitochondrial Transmembrane Potential, Cytochrome C Release and Caspase Activation. Int J Cancer 117, 318-325 (2005)
131. Iervolino A, D Trisciuoglio, D Ribatti, A Candiloro, A Biroccio, G Zupi, DD Bufalo: Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J 16, 1453-1455 (2002)
132. Letchoumy PV, KV Mohan, D Prathiba, Y Hara, S Nagini: Comparative evaluation of antiproliferative, antiangiogenic and apoptosis inducing potential of black tea polyphenols in the hamster buccal pouch carcinogenesis model. J Carcinog 3, 6-19 (2007)
133. Syed DN, F Afaq, MH Kweon, N Hadi, N Bhatia, VS Spiegelman, H Mukhtar: Green tea polyphenol EGCG suppresses cigarette smoke condensate-induced NF-kappaB activation in normal human bronchial epithelial cells. Oncogene 26, 673-682 (2007)
134. Morton JP, P Timpson, SA Karim, RA Ridgway, D Athineos, B Doyle, NB Jamieson, KA Oien, AM Lowy, VG Brunton, MC Frame, TR Evans, OJ Sansom: Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci 107, 246-251 (2010)
135. Isemura M, K Saeki, T Kimura, S Hayakawa, T Minami, M Sazuka. Tea catechins and related polyphenols as anti-cancer agents. Biofactors 13, 81-85 (2000)
136. Sazuka M, H Imazawa, Y Shoji, T Mita, Y Hara, M Isemura: Inhibition of collagenases from mouse lung carcinoma cells by green tea catechins and black tea theaflavins. Biosci Biotechnol Biochem 61, 1504-1506 (1997)
137. Mizuno H, YY Cho, F Zhu, WY Ma, AM Bode, CS Yang, CT Ho, Z Dong: Theaflavin-3, 3'-digallate induces epidermal growth factor receptor downregulation. Mol Carcinog 45, 204-212 (2006)
138. Agarwal ML, CV Ramana., M Hmilton, WR Taylor, SE Deprimo, LJ Bean, A Agarwal, MK Agarwal, A Wolfman, GR Stark: Regulation of p53 expression by the RAS-MAP kinase pathway. Oncogene. 20, 2527-2536 (2001)
139. Bhattacharya U, B Halder, S Mukhopadhyay, AK Giri: Role of oxidation-triggered activation of JNK and p38 MAPK in black tea polyphenols induced apoptotic death of A375 cells. Cancer Sci 100, 1971-1978 (2009)
140. Roy P, N Nigam, J George, S Srivastava, Y Shukla: Induction of apoptosis by tea polyphenols mediated through mitochondrial cell death pathway in mouse skin tumors. Cancer Biol Ther 8, 1281-1287 (2009)
141. Du Y, Y Wu, X Cao, W Cui, H Zhang, W Tian, M Ji, A Holmgren, L Zhong: Inhibition of mammalian thioredoxin reductase by black tea and its constituents: implications for anticancer actions. Biochimie 91, 434-444 (2009)
142. Halder B, U Bhattacharya, S Mukhopadhyay, AK Giri: Molecular mechanism of black tea polyphenols induced apoptosis in human skin cancer cells: involvement of Bax translocation and mitochondria mediated death cascade. Carcinogenesis 29, 129-38 (2008)
143. Kalra N, K Seth, S Prasad, M Singh, AB Pant, Y Shukla: Theaflavins induced apoptosis of LNCaP cells is mediated through induction of p53, down-regulation of NF-kappa B and mitogen-activated protein kinases pathways. Life Sci 80, 2137- 46 (2007)
144. Patel R, A Ingle, GB Maru: Polymeric black tea polyphenols inhibit 1,2-dimethylhydrazine induced colorectal carcinogenesis by inhibiting cell proliferation via Wnt/betacatenin pathway. Toxicol Appl Pharmacol 227, 136-46 (2008)
145. Way TD, HH Lee, MC Kao, JK Lin: Black tea polyphenol theaflavins inhibit aromatase activity and attenuate tamoxifen resistance in HER2/neu-transfected human breast cancer cells through tyrosine kinase suppression. Eur J Cancer 40, 2165-2174 (2004)
146. Huang GC, S Hobbs, M Walton, RJ Epstein: Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells. Br J Cancer 86, 1104-1109 (2002)
147. Leone M, D Zhai, S Sareth, S Kitada, JC Reed, M Pellecchia: Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res 63, 8118-8121 (2003)
148. Sultana H, J Kigawa, Y Kanamori, H Itamochi, T Oishi, S Sato, S Kamazawa, M Ohwada, M Suzuki, N Terakawa: Chemosensitivity and p53-Bax pathwaymediated apoptosis in patients with uterine cervical cancer. Ann Oncol 14, 214-219 (2003)
149. Sadava D, E Whitlock, SE Kane: The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. Biochem Biophys Res Commun 360, 233-237 (2007)
150. Zhang J, Y Tu, S Schneider: Activation of p53, inhibition of telomerase activity and induction of estrogen receptor beta are associated with the anti-growth effects of combination of ovarian hormones and retinoids in immortalized human mammary epithelial cells. Cancer Cell Int 5, 6 (2005)
151. Rana S, K Gupta, J Gomez, S Matsuyama, A Chakrabarti, ML Agarwal, A Agarwal, MK Agarwal, DN Wald. Securinine induces p73-dependent apoptosis preferentially in p53-deficient colon cancer cells. FASEB J. 24, 2126-2134 (2010)
152. Park AM, Z Dong: Signal transduction pathways: targets for green and black tea polyphenols. J Biochem Mol Biol 36, 66-77 (2003)
153. Ailles LE, IL Weissman: Cancer stem cells in solid tumors. Curr Opin Biotechnol 18, 460-466 (2007)
154. Chung KY, T Mukhopadhyay, J Kim, A Casson, JY Ro, H Goepfert, WK Hong, JA Roth: Discordant p53 Gene Mutations in Primary Head and Neck Cancers and Corresponding Second Primary Cancers of the Upper Aerodigestive Tract. Cancer Res 53, 1676-1683 (1993)
155. Meletis K, V Wirta, SM Hede, M Nistér, J Lundeberg, J Frisén: p53 suppresses the self-renewal of adult neural stem cells. Development 133, 363-369 (2006)
156. Cicalese A, G Bonizzi, CE Pasi, M Faretta, S Ronzoni, B Giulini, C Brisken, S Minucci, PP Di Fiore, PG Pelicci: The tumor suppressor p53 regulates polarity of selfrenewing divisions in mammary stem cells. Cell 138, 1083- 10895 (2009)
157. Leonova KI, J Shneyder, MP Antoch, IA Toshkov, LR Novototskaya, PG Komarov, EA Komarova, AV Gudkov: A small molecule inhibitor of p53 stimulates amplification of hematopoietic stem cells but does not promote tumor development in mice. Cell Cycle 9, 1434-1443 (2010)
158. A. Paulson http://deepblue.lib.umich.edu/bitstream/2027.42/63899/1/ (2009)
159. Zhang M, F Behbod, RL Atkinson, MD Landis, F Kittrell, D Edwards, D Medina, A Tsimelzon, S Hilsenbeck, JE Green, AM Michalowska, J M Rosen: Identification of tumor-initiating cells in a p53- null mouse model of breast cancer. Cancer Res 68,4674-4682(2008)
160. Godar S, TA Ince, GW Bell, D Feldser, JL Donaher, J Bergh, A Liu, K Miu, RS Watnick, F Reinhardt, SS McAllister, T Jacks, RA Weinberg: Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 134, 62-73 (2008)
161. Riley T, E Sontag, P Chen, A Levine: Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9, 402-412 (2008)
162. Jerry DJ, L Tao, H Yan: Regulation of cancer stem cells by p53. Breast Cancer Res 10, 304 (2008)
163. Colaluca IN, D Tosoni, P Nuciforo, F Matuglia, V Galimberti, G Viale: NUMB controls p53 tumour suppressor activity. Nature 451, 76-80 (2008)
164. Gunther EJ, SE Moody, GK Belka, KT Hahn, N Innocent, KD Dugan, RD Cardiff, LA Chodosh: Impact of p53 loss on reversal and recurrence of conditional Wntinduced tumorigenesis. Genes Dev 17, 488-501 (2003)